Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3Phase 3 2

Status

Completed 39Recruiting 8Terminated 7Unknown 4Not yet recruiting 4Active not recruiting 4Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Breast Neoplasms 184Carcinoma, Non-Small-Cell Lung 143Multiple Myeloma 118Prostatic Neoplasms 116Leukemia, Myeloid, Acute 75Colorectal Neoplasms 75Neoplasms 73Melanoma 71Squamous Cell Carcinoma of Head and Neck 65Lymphoma 64Lung Neoplasms 64Neoplasm Metastasis 63Pancreatic Neoplasms 55Ovarian Neoplasms 49Sarcoma 45Carcinoma, Renal Cell 44Triple Negative Breast Neoplasms 42Urinary Bladder Neoplasms 41Leukemia, Lymphocytic, Chronic, B-Cell 41Glioblastoma 41Carcinoma, Hepatocellular 41Recurrence 40Head and Neck Neoplasms 37Lymphoma, Large B-Cell, Diffuse 35Brain Neoplasms 35Myelodysplastic Syndromes 34Hematologic Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Lymphoma, Non-Hodgkin 33Lymphoma, Mantle-Cell 32

Interventions

Dexamethasone 2siltuximab 1pomalidomide 1ixazomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × Immunoglobulin Light-chain Amyloidosis × Clear all
NCT05951049 2026-05-06

A Study of AT-02 in Subjects With Systemic Amyloidosis.

Attralus, Inc.

Phase 2 Active not recruiting
120 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT04270175 2026-02-27

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Weill Medical College of Cornell University

Phase 2 Active not recruiting
15 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

NCT03618537 2025-12-04

Ixazomib Maintenance Study in Patients With AL Amyloidosis

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
17 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT03315026 2025-11-04

Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
30 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡